U.S. markets closed

  • S&P 500

    4,323.06
    +64.57 (+1.52%)
     

  • Dow 30

    34,511.99
    +549.95 (+1.62%)
     

  • Nasdaq

    14,498.88
    +223.89 (+1.57%)
     

  • Russell 2000

    2,194.30
    +63.62 (+2.99%)
     

  • Crude Oil

    67.32
    +0.90 (+1.36%)
     

  • Gold

    1,810.20
    +1.00 (+0.06%)
     

  • Silver

    24.97
    -0.18 (-0.71%)
     

  • EUR/USD

    1.1783
    -0.0022 (-0.19%)
     

  • 10-Yr Bond

    1.2090
    +0.0280 (+2.37%)
     

  • GBP/USD

    1.3625
    -0.0051 (-0.37%)
     

  • USD/JPY

    109.8460
    +0.3780 (+0.35%)
     

  • BTC-USD

    29,864.79
    -928.97 (-3.02%)
     

  • CMC Crypto 200

    716.20
    +13.99 (+1.99%)
     

  • FTSE 100

    6,881.13
    +36.74 (+0.54%)
     

  • Nikkei 225

    27,388.16
    -264.58 (-0.96%)
     

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Kiniksa Pharmaceuticals, Ltd.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1485623.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com


Recommended Stories

  • Netflix down after reporting mixed Q2 earnings

    Netflix reported mixed quarterly earnings. The company posted revenue of $7.34B and an EPS of $2.97 vs. the street estimated revenue of $7.32B and an estimated EPS of $3.14. Yahoo Finance’s Dan Howley joined Yahoo Finance Live to break down the key metrics.

  • Why AMC Stock Bounced Tuesday

    After virtually a month of steady declines in the stock, AMC's business is getting some good news today.

  • Why General Electric Stock Bounced Back Today

    Industrial behemoth General Electric (NYSE: GE) couldn't fight the tide yesterday. As Wall Street sold off on worries of a reinvigorated, Delta variant-fueled COVID-19 pandemic that would devastate demand for air travel -- and airplane engines -- shares of General Electric sold off as well. Remember, General Electric used to depend on sales of airplane engines to provide as much as 35% of its revenues.

  • Netflix beats expectations for new subscribers, misses on guidance

    Netflix reported its Q2 earnings on Tuesday, beating expectations on new users, but falling short of Q3 forecast expectations.

  • Why SolarWinds Stock Tanked More Than 40% Today

    Shares of SolarWinds (NYSE: SWI) are down more than 41% as of 11:10 a.m. EDT, according to data from S&P Global Market Intelligence. This was just days before it was revealed by security firm FireEye (NASDAQ: FEYE) that a breach on its systems was exploited through SolarWinds IT monitoring and management software Orion -- which FireEye and a slew of other tech companies and government agencies use, and through which Russian hackers had infiltrated their systems. It's been tough going for SolarWinds ever since.

  • Why Alcoa Stock Popped Today

    Alcoa (NYSE: AA) shares shot through the roof on Tuesday, jumping as high as 10.7% as of 2:40 p.m. EDT. With yet another analyst joining the bandwagon who believes Alcoa shares have significant upside ahead, more and more investors are betting on the stock. Morgan Stanley turned bullish about the metals and mining sector in June and singled out Alcoa as a top pick.

  • Virgin Galactic Stock Is Getting Clobbered After Blue Origin’s Success. Here’s Why.

    Galactic shares went from $15 to $50 over the course of about 2½ months starting in early May. That Icarus-like rise is as much as reason the stock is down today as the Blue Origin flight.

  • Is Now the Right Time to Buy Moderna Stock?

    Thanks to its globally in-demand coronavirus vaccine, Moderna (NASDAQ: MRNA) is one of the hottest companies on the market right now. In my view, Moderna will probably continue to outperform, but there's a solid chance that its growth could soon either slow down -- or potentially accelerate. The argument in favor of buying Moderna today is that its future revenue from vaccine sales will likely be even larger than today's.

  • Philip Morris Beat Earnings Estimates. Why Its Stock Is Dropping.

    The tobacco giant's full-year guidance was slightly below expectations, but the CFO says the company continues “to head in the right direction.”

  • Apple’s Earnings Are Next Week. Analysts Are Expecting More.

    The Street continues to ratchet up its forecasts for the company’s June quarter earnings report. Shares were higher on Tuesday afternoon.

  • Dow Jones Rallies As Boeing Fights Back; Virgin Galactic Falls As Bezos Blasts Off; AMC Surges

    The Dow Jones rallied as Boeing stock gained. Virgin Galactic stock fell as Jeff Bezos blasted into space. AMC stock was surging.

  • Chipotle posts big earnings beat as dine-in customers return in droves

    Chipotle blew away Wall Street's expectations in its Q2 earnings report.

  • Nvidia Stock - How to Trade It After the Split

    Nvidia stock has been getting hit hard lately, but it's still up notably from its May low. Let's look at the chart after its stock split went into effect.

  • NeuroMetrix stock more than triples on massive volume after fibromyalgia treatment gets FDA boost

    Shares of NeuroMetrix Inc. rocketed 241% toward a two-year high on record volume, after the Massachusetts-based medical device company said its Quell transcutaneous electric nerve stimulator received "Breakthrough Designation" from the Food and Drug Administration to treat fibromyalgia symptoms in adults. Trading volume ballooned to 228.3 million shares, compared with the full-day average over the past 30 days of about 125,600 shares, to make the stock the biggest gainer and most actively traded

  • 10 Cheap Monthly Dividend Stocks to Buy Now

    In this article, we will be looking at the 10 cheap monthly dividend stocks to buy now. To skip our detailed analysis of dividend investing and these companies, you can go directly to see the 5 Cheap Monthly Dividend Stocks to Buy Now. Within the world of dividend investing, there is quite a bit of diversity […]

  • Want to Buy Ford (F) Stock? Read This First.

    Ford is one of the biggest legacy stocks in America. Founded by Henry Ford and responsible for numerous advancements in the American automotive industry, Ford is currently tackling the electric and hybrid market by offering a hybrid Fusion, all-electric Mustang (which is almost unthinkable,) an all-electric F-150 (also previously unthinkable) and many more “green” vehicles—generating competition for automakers like Tesla while enjoying the visibility and brand loyalty of an established mark. Ste

  • Moderna Stock Hits Record High As Covid Vaccine Heads To India — Is It A Buy Right Now?

    Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride. Is Moderna stock a buy now?

  • Why N-able Stock Tumbled 12.6% in Its Market Debut

    The cloud-based IT service software company completed its spinoff from SolarWinds (NYSE: SWI), the tech-management company at the heart of a massive security breach that was revealed last December. Fortuitously, this was just days before cybersecurity firm FireEye revealed it was hacked through SolarWinds IT monitoring and management software Orion. It's been tough going for SolarWinds ever since, but spinning off N-able will allow the smaller software business to create some distance for itself from the embattled services that will remain under the SolarWinds name.

  • 2 Growth Stocks to Buy and Hold Forever

    Growth stocks, particularly those equipped to perform well amid the pandemic, were all the rage last year, and many of them doubled or even tripled in 2020. Case in point: Shares of telehealth giant Teladoc Health (NYSE: TDOC) are down by 26.6% year to date, while Square (NYSE: SQ) stock was recently up by 9%; by comparison, the S&P 500 has gained 15% on the year. Telehealth is one such example, and Teladoc is a leader in this field.

  • Why IBM Stock Rose Today

    IBM's revenue rose 3% year over year to $18.7 billion, fueled by a 6% rise in its cloud and cognitive software sales and a 12% jump in its business services revenue. "We continued to help clients infuse our AI-based technology offerings into their core business workflows," IBM CEO Arvind Krishna said in a press release. Its operating and adjusted free cash flow checked in at $2.6 billion and $1.6 billion, respectively, which allowed it to pay $1.5 billion in dividends to investors.